In the July 20, 2015, Federal Register, FDA requested that public stakeholders, including patient and consumer advocacy groups, health care professionals, and scientific and academic experts, notify FDA of their intent to participate in periodic consultation meetings on the reauthorization of the Prescription Drug User Fee Act ("PDUFA") for which the statutory authority expires in September 2017. FDA is required, under the Federal Food, Drug & Cosmetic Act ("FDCA") to consult with a range of stakeholders in developing recommendations for the next PDUFA program. Notifications of Intent are due August 28, 2015.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
